- 2 May 2019
1:00 pm - 2:00 pm
Thursday 2 May 2019, 1.00 PM
Auditorium, Level 6, BANCROFT Building
New targets in immunooncology
Professor Mark Smyth,
Immunology in Cancer and Infection,
QIMR Berghofer Medical Research Institute
We have explored the mechanism of action of novel anti-mouse and anti-human monoclonal antibodies and other agents that target various immune cells in the tumor microenvironment. These include targeting the CD96/TIGIT/CD226-CD155 immune complex bridging lymphocytes and tumour cells or myeloid cells, targeting CD39 the ectoenzyme at the apex of the cascade that converts ATP into immunosuppressive adenosine, and targeting eIF2α phosphatase (eIF2α-p), by a safe and selective small molecule inhibitor Sephin1, to inhibit ER stress response of tumor infiltrating immune cells. Collectively, these provide novel methods to reduce myeloid immune suppression, enhance intratumor T cell effector function, overcome anti-PD-1 resistance, and potentially enhance adoptive T cell transfer.
Professor Mark Smyth (FAA, FAHMS) is a Senior Scientist and Immunology Coordinator at QIMR Berghofer Medical Research Institute. He completed his PhD in 1988 and trained at the NCI (1988–1992), before commencing his independent research career in Australia. Over the last 20 years he rekindled world-wide interest in cancer immune surveillance, defined immune-mediated dormancy of cancer, and the role of the host immunity in chemotherapy and targeted therapy responses. More recently, he has provided new means of classifying natural killer cell (NK) subtypes and three new targets for cancer immunotherapy. He is a past winner of the William Coley Medal and Charles Brupbacher Foundation Prizes in Cancer Research. He has a number of scientific research agreements, consultancies, new patents and other patents licenced to industry. He has an H-Index of 144, is the highest cited immunologist in Australia, and is a Senior Editor, and Advisory Board Member for Cancer Immunology Research and Science, respectively.